Usefulness of N-terminal-pro B-type natriuretic peptide as a heart failure marker in patients undergoing percutaneous left atrial appendage occlusion

Abstract

Background: The left atrial appendage is involved in secretion of N-terminal-pro B-type natriuretic peptide (NT-proBNP). Percutaneous left atrial appendage occlusion (LAAO) for prevention of stroke may cause variations in NT-proBNP release. Aim: This study aimed to assess the diagnostic value of NT-proBNP after LAAO. Methods: The study group comprised 53 patients in whom LAAO was performed. The patients with heart failure (HF) and reduced ejection fraction (EF) were allocated to group I (n = 16) whereas patients with no HF symptoms and EF > 40% were allocated to group II (n = 37). The symptomatic patients with EF > 40% were excluded. NT-proBNP values were measured prior to LAAO, at one–two days, and at three-month follow-up. EF, six-minute walk test (6MWT), and peak oxygen consump¬tion (VO2max) were assessed 24 h prior to LAAO and after three months. Results: Prior to LAAO the NT-proBNP level was higher in group I, when compared to group II (3084.74 ± 559.53 pg/mL vs. 808.02 ± 115.83 pg/ml, p < 0.01). In both groups there was a nonsignificant increase in NT-proBNP level at one–two days after LAOO (3100.14 ± 690.08 pg/mL in group I and 1012.09 ± 166.71 pg/mL in group II). At the three-month follow-up a fur¬ther increase of NT-proBNP level in group I (3852.73 ± 1025.78 pg/mL) and a decrease in group II (855.03 ± 107.49 pg/mL) was observed. The pairwise comparison between the means of 6MWT and VO2max showed no significant changes during follow-up. At baseline, NT-proBNP level of 988 pg/mL presented 87.5% sensitivity and 75.7% specificity for prediction of HF. Three months after LAAO, it increased to 1358 pg/mL (sensitivity 81.2%, specificity 78.4%). Conclusions: When diagnosing HF in atrial fibrillation patients, the higher cut-off value of NT-proBNP should be used. NT-proBNP remains an appropriate diagnostic marker of HF in patients after LAAO.